Surgical and Biologic Outcomes After Neoadjuvant Bicalutamide Treatment in Prostate Cancer

Urology

Volumn 70, Issue 4, 2007, Pages 728-733

  Gravina, Giovanni Luca ^a   Festuccia, Claudio ^a   Galatioto, Giuseppe Paradiso ^a   Muzi, Paola ^a   Angelucci, Adriano ^a   Ronchi, Piero ^a   Costa, Alessia Mariagrazia ^a   Bologna, Mauro ^a   Vicentini, Carlo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST TENDERNESS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GYNECOMASTIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TOSYL COMPOUNDS; UP-REGULATION;

EID: 35648937519     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.05.024     Document Type: Article

References (24)

1. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 167 (2002) 528-534
2. Selli C., Montironi R., Bono A., et al. Effect of complete blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 55 (2002) 508-513
3. Lupron Depot Neoadjuvant Prostate Cancer Study Group, Solaway M.S., Sharifi R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy precede by androgen blockade in clinical stage (T2bNxM0) prostate cancer. J Urol 154 2 Pt 1 (1995) 424-428
4. Canadian Urologic Oncology Group, Klotz L.H., Goldemberg S.L., Jewett M., et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36 months post treatment PSA results. Urology 49 suppl 3A (1997) 46-55
5. Unni E., Sun S., Nan B., et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64 (2004) 7156-7168
6. Pendleton J., Pister L.L., Nakamura K., et al. Neoadjuvant therapy before radical prostatectomy: where have we been?. Where are we going?. Urol Oncol Semin Orig Invest 25 (2007) 11-18
7. Mass R.D. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58 (2004) 932-940
8. Gross M.E., Shazer R.L., and Agus D.B. Targeting the HER-kinase axis in cancer. Semin Oncol 31 suppl 3 (2004) 9-20
9. Craft N., Shostak Y., and Carey M. A mechanism of hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 (1999) 280-285
10. Gravina G.L., Festuccia C., Angelucci A., et al. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int J Oncol 25 (2004) 97-104
11. Festuccia C., Angelucci A., Gravina G.L., et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity: EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 93 (2005) 964-975
12. Holbro T., Civenni G., and Hynes N.E. The erbB receptors and their role in cancer progression. Exp Cell Res 284 (2003) 299-310
13. Bostwick D.G. Evaluating prostate needle biopsy: therapeutic and prognostic importance. Ca Cancer J Clin 47 (1997) 297-319
14. In: Sobin L.H., and Wittekind C. (Eds). TNM Classification of Prostate Cancer. 6th ed. (2002), Wiley-Liss, New York
15. Selli C., Montironi R., Bono A., et al. Effect of complete blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 55 (2002) 508-513
16. Osman I., Sher H.I., Drobnjak M., et al. Her2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7 (1999) 2643-2647
17. Nunes R.A., and Harris L.N. The Her2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 3 (2002) 125-133
18. Colomer R., Montero S., Lluch A., et al. Circulating Her2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6 (2000) 2356-2364
19. Lipton A., Ali S.M., Leitzel K., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20 (2002) 1467-1472
20. Edwards J., Traynor P., Munro A.F., et al. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12 (2006) 123-130
21. Pilepich M.V., Winter K., and John M.J. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
22. Laverdiere J., Gomez J.L., and Cusan L. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
23. Laverdiere J., Nabid A., De Bedoya L.D., et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171 (2004) 1137-1140
24. Zelefsky M.J., and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 49 suppl 3A (1997) 38-45